Work

Front Cover: Chromenone Derivatives as CRM1 Inhibitors for Targeting Glioblastoma (ChemBioChem 15/2025)

Year: 2025

Type: paratext

Abstract: The cover image illustrates the inhibition of the nuclear export receptor CRM1 by a small molecule inhibitor (in red) that covalently binds to cysteine at position 528. CRM1, a ring-shaped protein, is overexpressed in several human cancers, including glioblastoma (GBM). Its inhibition can disrupt three key oncogenic signaling pathways that drive GBM progression. CRM1 facilitates the nuclear export of proteins containing a nuclear export signal through the nuclear pore complex (depicted in yellow), which is embedded in the nuclear envelope, from the nucleus to the cytoplasm. More details can be found in the article 10.1002/cbic.202500195 by Wolfgang Link and co-workers.

Source: ChemBioChem

DOI: 10.1002/cbic.70013

Authors: Salvatore Princiotto, Lucía Jiménez, Lucía Domínguez, João G. N. Sequeira, Cristiana Mourato, Alba Orea‐Soufi, Bruno Santos, Sabrina Dallavalle, Miguel Machuqueiro, Bibiana I. Ferreira, Wolfgang Link

Institutions: University of Milan, Consejo Superior de Investigaciones Científicas, Instituto de Investigaciones Biomédicas Sols-Morreale, Universidad Autónoma de Madrid, University of Lisbon, Algarve Biomedical Center, University of Algarve

Language: English

Topic: Nuclear Structure and Function

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4413498800

Cites:

Cited by:

Related to: 10